RESUMO
Previous research reports that populations with HIV consume higher rates of alcohol than general population. This cross-sectional study (n = 391) was conducted to measure alcohol consumption, factors associated with consumption, and the relationship between alcohol and HIV viral loads among individuals receiving HIV care. Increased alcohol consumption was associated with being male, lower education attainment, and lacking a current HAART prescription. Additionally, among those currently on HAART, unsuppressed viremia was associated with higher levels of alcohol consumption. These findings suggest that there may be a relatively low level of alcohol consumption that is detrimental to virologic suppression among populations with HIV.
Assuntos
Consumo de Bebidas Alcoólicas/epidemiologia , Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Carga Viral , Adolescente , Adulto , Instituições de Assistência Ambulatorial , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Estudos Transversais , Feminino , Infecções por HIV/virologia , Nível de Saúde , Humanos , Masculino , Adesão à Medicação , Pessoa de Meia-Idade , Missouri/epidemiologia , RNA Viral , Fatores de Risco , Fatores Socioeconômicos , Inquéritos e Questionários , Viremia/tratamento farmacológico , Viremia/virologia , Adulto JovemRESUMO
OBJECTIVES: Frailty among HIV-infected persons is increasingly recognized but data are limited. We aimed to determine frailty prevalence, predictors and clinical significance in this population. METHODS: This was a prospective cross-sectional study of HIV-infected persons > or =18 years attending Washington University HIV Clinics between June and December 2008. Frailty was defined by > or =3 of 5 criteria: weight loss, low physical activity, exhaustion, weak grip strength and slow walking time. Independent predictors of frailty were evaluated using multivariate logistic regression analyses. RESULTS: 445 persons were studied; mean age 41.7 years, 71% male, 63% African American with a mean 8.4 years since HIV diagnosis. 75% were on antiretroviral therapy with median CD4+437 cells/mm(3). Frailty prevalence was 9%. Independent predictors of frailty included unemployment, greater number of comorbid conditions and past opportunistic illnesses, higher depression severity score, receipt of antidepressants and lower serum albumin. Hospitalization rates were greater for frail persons with a five-fold longer duration of inpatient stay. CONCLUSION: HIV infection was associated with a premature presentation of frailty. Frailty was associated with greater comorbidity, markers of advanced immunodeficiency and adverse socioeconomic and clinical outcomes. Further study of frailty in patients with HIV infection is warranted.
